In vivo activity assessment of a concentrated AXO-AAV-OPMD clinical construct that simultaneously expresses anti-PABN1 shRNA and a codon optimized PABPN1

Project: Research

StatusFinished
Effective start/end date1/12/1820/09/19

Funding

Axovant Sciences Inc: £194,748

ID: 36028211